论文部分内容阅读
目的 探讨TRAILR在肝细胞肝癌 (hepatocellularcarcinoma ,HCC)中的表达及其临床意义。方法 采用原位杂交方法检测了 6 0例肝癌组织、两种肝癌细胞株以及 2 0例正常肝组织中TRAILR的表达 ,并结合临床资料进行分析。结果 6 0例肝癌组织及 2 0例正常肝组织均表达死亡受体DR5和DR4,但肝癌组织DR表达量显著强于正常肝组织DR表达量。 5 4例肝癌组织不表达诱捕受体DcR1( 90 % ) ,2 5例肝癌组织不表达DcR2 ( 41.7% ) ,而 2 0例正常肝组织均表达DcR。肝癌组织中DR的高表达及DcR的低表达不同于正常肝组织中DR的低表达及DcR的高表达 ,两者间有显著差异性。两种肝癌细胞株中均检测到DR5、DR4、DcR2的表达 ,但DcR1表达缺失。HCC组织中DR的表达与肿瘤的分化、肿瘤分级有关 ,低分化的肿瘤DR表达减少 (P <0 .0 1) ,Ⅲ /Ⅳ期肿瘤DR的表达显著低于Ⅰ/Ⅱ级DR表达 (P <0 .0 5 )。DR的表达与病人的性别、年龄、HBsAg阳性与否、AFP水平、肿瘤的大小以及是否转移无关。肿瘤细胞耐药株DR表达降低。结论 HCC普遍存在TRAILR的表达 ,并存在受体类型的表达差异。DcR1的表达大多缺失有利于TRAIL治疗HCC。
Objective To investigate the expression of TRAILR in hepatocellular carcinoma (HCC) and its clinical significance. Methods The expression of TRAILR in 60 liver cancer tissues, 2 hepatocellular carcinoma cell lines and 20 normal liver tissues was detected by in situ hybridization and analyzed with clinical data. Results The death receptor DR5 and DR4 were expressed in 60 liver cancer tissues and 20 normal liver tissues, but the expression of DR in liver cancer tissues was significantly higher than that in normal liver tissues. In 54 liver cancer tissues, DcR1 (90%) was not expressed, while 25 cases of HCC did not express DcR2 (41.7%), while 20 cases of normal liver tissue expressed DcR. The high expression of DR and the low expression of DcR in hepatocellular carcinoma are different from the low expression of DR and the high expression of DcR in normal liver tissue, with significant difference between the two. DR5, DR4 and DcR2 were detected in both hepatocellular carcinoma cell lines, but the expression of DcR1 was absent. The expression of DR in HCC tissues was related to tumor differentiation and tumor grade, the expression of DR in poorly differentiated tumors decreased (P <0.01), the expression of DR in stage Ⅲ / Ⅳ tumors was significantly lower than that in stage Ⅰ / Ⅱ (P <0 .0 5). DR expression and the patient’s gender, age, HBsAg-positive or not, AFP level, tumor size and whether the transfer has nothing to do. The expression of DR in tumor cells decreased. Conclusions The expression of TRAILR is common in HCC, and there are differences in the expression of TRAILR. Most of the loss of DcR1 expression favors TRAIL in the treatment of HCC.